Shares of Novo Nordisk Inc. (NYSE: NVO) are trading lower Tuesday after a new study raised concerns about a potential link ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

The drug candidate, trevogrumab, in combination with Novo Nordisk's popular obesity drug Wegovy, chemically known as semaglutide, helped patients preserve muscle and increase fat loss in patients, ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Novonesis leads in enzymes and biosolutions with strong growth, margins, and strategy, but valuation calls for patience. See ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Novo Nordisk should perform well thanks to new leadership and a strong underlying business. Exelixis' main oncology franchise ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

UnitedHealth Group (NYSE:UNH) has faced severe headwinds in 2025, with its stock plummeting over 50% from its April high.

Stock futures jumped after a court struck down Trump's sweeping tariff agenda. The Court of International Trade on Wednesday ruled that Trump wrongfully invoked an emergency law to impose tariffs on ...